Esperion Therapeutics Statistics, Revenue Totals, Facts & News (2022)
Last Updated on: April 13th, 2022
Here are a few of the most interesting Esperion Therapeutics statistics and facts I was able to dig up including revenue totals and employee counts. As always, be sure to check back in the future as I will be updating this post as new and updated stats become available.
Esperion Therapeutics Facts
- Esperion Therapeutics Website: Official Website
- Year Esperion Therapeutics was Founded: 2008
- Esperion Therapeutics Headquarters: Ann Arbor, MI
- Esperion Therapeutics Founder(s): Dr Roger Newton
- Current Esperion Therapeutics Chief Executive: Timothy Mayleben
What is Esperion Therapeutics?
Official LinkedIn page for Esperion. Esperion is The Lipid Management Company. Our team of lipid experts works to lower bad cholesterol by discovering, developing and commercializing innovative medicines and combinations with established medicines. We work hard to make our medicines easy to take, easy to get and easy to have. We are singularly focused on disrupting high cholesterol so you can improve your health – easily. (source)
Esperion Therapeutics Employee Count
Number of Esperion Therapeutics employees:
Last updated 1/1/20
Esperion Therapeutics Revenue Totals
Esperion Therapeutics annual revenue:
- 2021: $78 million
- 2020: $227 million
- 2019: $148 million
Esperion Therapeutics annual net income:
- 2021: $269.1 million net loss
- 2020: $143.5 million net loss
- 2019: $97.1 million net loss
- 2018: $201.8 million net loss
- 2017: $166.9 million net loss
- 2016: $74.9 million net loss
- 2015: $49.7 million net loss
Please note that some of these numbers are easier to find than others. A few of these Esperion Therapeutics statistics come from their own reports, but some are based on news reports and not official company tallies. No information contained on DMR should be relied upon to make investment decisions. Basically, this is the best I can find and I don’t guarantee anything to be 100%.
Related Categories:
Related Tags: